Ralfinamide: Completed Phase IIb/III enrollment

Newron completed enrollment of 411 patients in the double-blind, international Phase IIb/III SERENA trial comparing 160 or 320 mg/day oral ralfinamide vs. placebo for 12 weeks. Patients completing the...